Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared With Sham in Subjects With Macular Edema Secondary to Branch Retinal Vein Occlusion

NCT00486018 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT00486018
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00486018 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared With Sham in Subjects With Macular Edema Secondary to Branch Retinal Vein Occlusion
Lead sponsor
Genentech, Inc.
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2007
Completion date
November 30, 2009
Enrollment
397 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

macular edema, retinal vein occlusion